| Autor: |
Bakasis AD; Department of Pathophysiology, Medical School, National and Kapodistrian University of Athens, 11527 Athens, Greece., Bitzogli K; Department of Pathophysiology, Medical School, National and Kapodistrian University of Athens, 11527 Athens, Greece., Mouziouras D; Department of Pathophysiology, Medical School, National and Kapodistrian University of Athens, 11527 Athens, Greece., Pouliakis A; Second Department of Pathology, Medical School, National and Kapodistrian University of Athens, 11527 Athens, Greece., Roumpoutsou M; Department of Pathophysiology, Medical School, National and Kapodistrian University of Athens, 11527 Athens, Greece., Goules AV; Department of Pathophysiology, Medical School, National and Kapodistrian University of Athens, 11527 Athens, Greece., Androutsakos T; Department of Pathophysiology, Medical School, National and Kapodistrian University of Athens, 11527 Athens, Greece. |
| Abstrakt: |
The novel mRNA-based vaccines against SARS-CoV-2 display encouraging safety and efficacy profiles. However, there is a paucity of data regarding their immunogenicity and safety in patients with liver diseases (PWLD), especially in those with cirrhosis. We prospectively assessed anti-SARS-CoV-2 S-spike IgG antibodies and neutralizing activity in fully vaccinated PWLD ( n = 87) and controls ( n = 40). Seroconversion rates were 97.4% (37/38) in cirrhotic PWLD, 87.8% (43/49) in non-cirrhotic PWLD and 100% (40/40) in controls. Adequate neutralizing activity was detected in 92.1% (35/38), 87.8% (43/49) and 100% (40/40) of cirrhotics, non-cirrhotics and controls, respectively. On multivariable analysis, immunosuppressive treatment was negatively correlated with anti-SARS-CoV-2 antibody titers (coefficient (SE): -2.716 (0.634), p < 0.001) and neutralizing activity (coefficient (SE): -24.379 (4.582), p < 0.001), while age was negatively correlated only with neutralizing activity (coefficient (SE): -0.31(0.14), p = 0.028). A total of 52 responder PWLD were reassessed approximately 3 months post-vaccination and no differences were detected in humoral responses between cirrhotic and non-cirrhotic PWLD. No significant side effects were noted post vaccination, while no symptomatic breakthrough infections were reported during a 6-month follow up. Overall, our study shows that m-RNA-based SARS-CoV-2 vaccines are safe and efficacious in PWLD. However, PWLD under immunosuppressive treatment and those of advanced age should probably be more closely monitored after vaccination. |
